

REMARKS

The sequence listing has been amended to correct errors in the sequences set forth in SEQ ID NOS:1-8. These sequences as provided in the originally filed listing were intended to match sequences shown in Figure 2, but did not. The sequences set forth in SEQ ID NOS:1-8 as included in the replacement listing correspond to those shown in Figure 2. The content of Figure 2 has not changed. Thus, no new matter has been added by correction of the sequence listing.

The specification has been amended such that the descriptions of Figures 1 and 2 correspond to the formal drawings submitted herewith. For example, the description of Figure 2 has been amended to state that residues conserved in CD28, CTLA-4, and/or ICOS are shown in bold rather than shaded. No new matter has been added by these amendments to the specification.

Applicant asks that all claims be examined. No fees are believed due. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: March 13, 2003

Elizabeth N. Kaytor
Elizabeth N. Kaytor, Ph.D.
Reg. No. P-53,103

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696



Version with markings to show changes made

In the specification:

The paper copy of the sequence listing and the sequence listing on computer readable diskette have been replaced with the enclosed paper copy and diskette.

The paragraph beginning at page 3, line 12, has been amended as follows:

FIG. 1 is a histogram showing the binding of human and mouse ICOSIg to human B7-H2. CHO cells were transfected with a human B7-H2 plasmid (open histograms) or vector control (shaded histogram), stained with human ([solid] right line) or mouse ([dotted] left line) ICOSIg, and analyzed by flow cytometry.

The paragraph beginning at page 3, line 16 has been amended as follows:

FIG. 2 is a sequence alignment of the extracellular Ig-domains of mouse, rat, human, and bovine CTLA-4, mouse, rat, bovine, and human CD28, and mouse and human ICOS (SEQ ID NO:1 through SEQ ID NO:10, respectively; m, mouse; r, rat; h, human; b, bovine). β -strands observed in the solution structure of human CTLA-4 are labeled by letter; assignments of residues to the A and C'' strands are tentative. Residue numbers are given for human ICOS. Ig V-set consensus residues and other hydrophobic core residues are shown in lower case. These are important for maintaining structural integrity but are not available for ligand binding. Other residues that are conserved in CD28, CTLA-4, and/or ICOS are [shaded] shown in bold. Conservative residue replacements (e.g., Y/F, R/K, and E/Q) are taken into account. Residues that are conserved in CD28 and CTLA-4 and are critical for CD80/CD86 binding are labeled with asterisks. Potential N-linked glycosylation sites are boxed. The positions of ICOS residues subjected to site-specific mutagenesis are labeled with exclamation points.